Pembrolizumab
Nome Comercial : Keytruda
Alvo : PD-1
Tipo Molecular : Anticorpo Monoclonal
Vendas em 2025 (Milhões de USD) : 30990
Todas as informações detalhadas do produto estarão sujeitas ao COA final emitido.
Caso necessite de documentação mais aprofundada para este item, por favor, entre em contato conosco.
Bevacizumab, Avastin, VEGF, Anticorpo monoclonal anti- VEGF, Anticorpo monoclonal anti- VEGF, Anticorpo IgG1 humanizado, Terapia biológica oncológica / antiangiogênica, CAS n.o 216974-75-3
Trade Name : Avastin Target : VEGF Molecular Type : Monoclonal Antibody Sales in 2025 (Millions of USD) : N/A All detailed product information shall be subject to the issued final COA. Should you need further in-depth documentation for this item, kindly get in touch with us.
Vedolizumab, Entyvio, MLN0002, Biológico anti-integrina, Anticorpo monoclonal IgG1 humanizado, Terapêutico da DII / Biológico da colite ulcerosa / Biológico da doença de Crohn, CAS n.o 943609-66-3
Trade Name : Entyvio Target : N/A Molecular Type : N/A Sales in 2025 (Millions of USD) : N/A All detailed product information shall be subject to the issued final COA. Should you need further in-depth documentation for this item, kindly get in touch with us.
Imiglucerase,Cerezyme,rGCR,GBA (β- glucocerebrosidase), Glicoproteína (Esta é uma proteína que contém 497 aminoácidos, produzida utilizando tecnologia de ADN recombinante), n.o CAS 154248-97-2
Trade Name : Cerezyme® Target : GBA (β- glucocerebrosid ase) Molecular Type : Glycoprotein (This is a protein containing 497 amino acids, produced using recombinant DNA technology) Sales in 2025 (Millions of USD) : 1105(estimate) All detailed product information shall be subject to the issued final ...
Luspatercept-aamt
Trade Name : Reblozyl Target : Transforming growth factor-β (TGF- β)superfamily ligands Molecular Type : Recombinant Fusion Protein Sales in 2025 (Millions of USD) : 2000 All detailed product information shall be subject to the issued final COA. Should you need further in-depth documentation for ...
